Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lineage Cell TherapeuticsFRA:BT3 78 PS Ratio is 19.19 as of Jul. 17, 2026, which is 79% below its 10-year median of 90.90. GuruFocus rates FRA:BT3 with a GF Score™ of 78/100 and a GF Value™ of €1.17. The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Lineage Cell Therapeutics ranks worse than 64.19% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lineage Cell Therapeutics's share price is €1.036.
Lineage Cell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.05. Hence, Lineage Cell Therapeutics's PS Ratio for today is 19.19.
Good Sign:
Lineage Cell Therapeutics Inc stock PS Ratio (=18.57) is close to 1-year low of 18.57.
The historical rank and industry rank for Lineage Cell Therapeutics's PS Ratio or its related term are showing as below:
FRA:BT3'
s PS Ratio Range Over the Past 10 Years
Min: 8.91 Med: 90.9 Max: 600
Current: 18.57
During the past 13 years, Lineage Cell Therapeutics's highest PS Ratio was 600.00. The lowest was 8.91. And the median was 90.90.
FRA:BT3's PS Ratio is ranked worse than 64.19% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs FRA:BT3: 18.57
Lineage Cell Therapeutics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Lineage Cell Therapeutics was 37.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 49.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 14.40% per year.
During the past 13 years, Lineage Cell Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 118.30% per year. The lowest was -51.60% per year. And the median was -6.10% per year.
Back to Basics: PS Ratio
Lineage Cell Therapeutics (FRA:BT3) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lineage Cell Therapeutics PS Ratio Related Terms
Lineage Cell Therapeutics PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lineage Cell Therapeutics's Share Price of today is €1.036. Lineage Cell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lineage Cell Therapeutics (FRA:BT3) has a PS Ratio of 19.19 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lineage Cell Therapeutics and its competitors. This is 79% below median its historical median of 90.90. Over the past decade, Lineage Cell Therapeutics' PS Ratio has ranged from 8.91 to 600.00. According to the industry distribution chart, Lineage Cell Therapeutics ranks #597 out of 930 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Lineage Cell Therapeutics' PS Ratio too high?
Lineage Cell Therapeutics' current PS Ratio of 19.19 is 79% below median its 10-year median of 90.90. Over the past 10 years, this metric has ranged from a low of 8.91 to a high of 600.00. The Biotechnology industry median PS Ratio is 9.30. Lineage Cell Therapeutics' value of 19.19 is 106.3% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #597 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' PS Ratio compare to NWBO and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #597 out of 930 companies for PS Ratio. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.30. Lineage Cell Therapeutics' value of 19.19 is 106.3% above this benchmark. Historically, Lineage Cell Therapeutics' own PS Ratio has ranged from 8.91 to 600.00 over the past decade. While the company's 10-year median is 90.90 vs. the industry median of 9.30, Lineage Cell Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current PS Ratio of 19.19 is 106.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current PS Ratio is 19.19, which is 79% below median its own 10-year median of 90.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Lineage Cell Therapeutics (FRA:BT3) has a current PS Ratio of 19.19. The stock's GF Value™ is €1.17, compared to a current price of €1.04 — trading 11.5% below its estimated fair value. The current PS Ratio is 19.19, which is 79% below median its 10-year median of 90.90 and 106.3% above the Biotechnology industry median of 9.30. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lineage Cell Therapeutics (FRA:BT3), the current PS Ratio is 19.19 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (FRA:BT3) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of €1.04 is trading 11.5% below its estimated GF Value™ of €1.17.
Key valuation signals for FRA:BT3:
PS Ratio: 19.19 (79% below median its 10-year median of 90.90)
GF Value™: €1.17 vs. price of €1.04 (11.5% below fair value)
Industry Position: 106.3% above the Biotechnology median (#597 of 930)
No single metric tells the full story. See the FRA:BT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for FRA:BT3
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BT3 has been successfully added to your 
